The molecular biology of mixed lineage leukemia
- PMID: 19535349
- PMCID: PMC2704309
- DOI: 10.3324/haematol.2008.002436
The molecular biology of mixed lineage leukemia
Abstract
Mixed lineage leukemia is a very aggressive blood cancer that predominantly occurs in pediatric patients. In contrast to other types of childhood acute leukemias, mixed lineage leukemia presents with a dismal prognosis and despite the availability of advanced treatment methods cure rates have stagnated over the last years. Mixed lineage leukemia is characterized by the presence of MLL fusion proteins that are the result of chromosomal translocations affecting the MLL gene at 11q23. These events juxtapose the amino-terminus of the histone methyltransferase MLL with a variety of different fusion partners that destroy normal histone methyltransferase function of MLL and replace it by heterologous functions contributed by the fusion partner. The resulting chimeras are transcriptional regulators that take control of targets normally controlled by MLL with the clustered HOX homeobox genes as prominent examples. Recent studies suggested that MLL fusion partners activate transcription by two different mechanisms. Some of these proteins are themselves chromatin modifiers that introduce histone acetylation whereas other fusion partners can recruit histone methyltransferases. In particular, histone H3 specific methylation at lysine 79 catalyzed by DOT1L has been recognized as a hallmark of chromatin activated by MLL fusion proteins. Interestingly, several frequent MLL fusion partners seem to coordinate DOT1L activity with a protein complex that stimulates the elongation phase of transcription by phosphorylating the carboxy-terminal repeat domain of RNA polymerase II. The discovery of these novel enzymatic activities that are essentially involved in MLL fusion protein function presents potential new targets for a rational drug development.
Figures
Similar articles
-
The pathogenesis of mixed-lineage leukemia.Annu Rev Pathol. 2012;7:283-301. doi: 10.1146/annurev-pathol-011811-132434. Epub 2011 Oct 17. Annu Rev Pathol. 2012. PMID: 22017583 Free PMC article. Review.
-
The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.J Hematol Oncol. 2020 Jun 17;13(1):78. doi: 10.1186/s13045-020-00909-y. J Hematol Oncol. 2020. PMID: 32552847 Free PMC article.
-
Disordered epigenetic regulation in MLL-related leukemia.Int J Hematol. 2012 Oct;96(4):428-37. doi: 10.1007/s12185-012-1180-0. Epub 2012 Sep 29. Int J Hematol. 2012. PMID: 23054645 Review.
-
Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3901-6. doi: 10.1073/pnas.1301045110. Epub 2013 Feb 14. Proc Natl Acad Sci U S A. 2013. PMID: 23412334 Free PMC article.
-
NUP98-MLL fusion in human acute myeloblastic leukemia.Blood. 2010 Sep 30;116(13):2332-5. doi: 10.1182/blood-2010-04-277806. Epub 2010 Jun 17. Blood. 2010. PMID: 20558618
Cited by
-
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Exp Hematol. 2015 Aug;43(8):698-712. doi: 10.1016/j.exphem.2015.05.001. Epub 2015 May 28. Exp Hematol. 2015. PMID: 26027790 Free PMC article. Review.
-
HOXA9 Regulome and Pharmacological Interventions in Leukemia.Adv Exp Med Biol. 2024;1459:405-430. doi: 10.1007/978-3-031-62731-6_18. Adv Exp Med Biol. 2024. PMID: 39017854 Review.
-
Cancer genetics and epigenetics: two sides of the same coin?Cancer Cell. 2012 Jul 10;22(1):9-20. doi: 10.1016/j.ccr.2012.06.008. Cancer Cell. 2012. PMID: 22789535 Free PMC article. Review.
-
Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners.J Mol Diagn. 2010 Jul;12(4):441-52. doi: 10.2353/jmoldx.2010.090214. Epub 2010 Jun 10. J Mol Diagn. 2010. PMID: 20539022 Free PMC article.
-
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.Cancer Cell. 2019 Dec 9;36(6):660-673.e11. doi: 10.1016/j.ccell.2019.11.001. Cancer Cell. 2019. PMID: 31821784 Free PMC article.
References
-
- Stass S, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood. 1984;64:701–6. - PubMed
-
- Mirro J, Kitchingman G, Williams D, Lauzon GJ, Lin CC, Callihan T, et al. Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation. Blood. 1986;67:689–97. - PubMed
-
- Mirro J, Kitchingman GR, Williams DL, Murphy SB, Zipf TF, Stass SA. Mixed lineage leukemia: the implications for hematopoietic differentiation. Blood. 1986;68:597–9. - PubMed
-
- Mirro J, Zipf TF, Pui CH, Kitchingman G, Williams D, Melvin S, et al. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood. 1985;66:1115–23. - PubMed
-
- Morse HG, Heideman R, Hays T, Robinson A. 4;11 translocation in acute lymphoblastic leukemia: a specific syndrome. Cancer Genet Cytogenet. 1982;7:165–72. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials